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ABSTRACT Moxiﬂoxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of
therapy.Weexaminedtheinteractionofmoxiﬂoxacinplusrifampinforlog-phaseandnonreplicatingpersister(NRP)organ-
isms.Forthisevaluation,weemployedourhollow-ﬁberinfectionmodel,inwhichorganismsareexposedtoclinicallyrelevant
drugconcentration-timeproﬁlesandtheimpactonbacterialcellkillandresistantsubpopulationampliﬁcationisdetermined.
Inlogphase,resistanceemergencewasobservedinallmonotherapyregimensandinnocombinationtherapyregimen.Nodif-
ferencewasseenintimetoa3-logreductioninthebacterialburden;therewasasigniﬁcantdifferenceintimetoresistanceemer-
gence(P0.0006).IntheNRPexperiment,noresistanceemergencewasseen.Therewasasigniﬁcantdifferencebetweenthe
monotherapyandcombinationtherapyregimensintimetoa3-logreductioninthebacterialburden(P0.042).Thecombina-
tionisefﬁcaciousforsuppressingresistantorganismsbutisantagonisticforcellkill.
IMPORTANCE M. tuberculosis infects one-third of the world’s population. Multiresistant organisms have become more frequent,
threateningourabilitytoprovideadequatechemotherapy.Moxiﬂoxacinhasbeenseenasanimportantnewagentwiththepo-
tential to supplant isoniazid or add to the rifampin/isoniazid combination. M. tuberculosis also exists in different physiological
states, including the nonreplicating persister phenotype. We examined the moxiﬂoxacin/rifampin combination in a new in vitro
systemtoallowjudgmentofhowmoxiﬂoxacinwouldinteractwithrifampinandallowitsperformanceinclinicaltrialstobe
placedintoperspective.Importantly,thecombinationsuppressedresistanceemergence,butatthepriceofslightlyslowingbac-
terialcellkill.Thisnewcombinationisawelcomeadditiontothephysician’sarmamentarium.
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M
oxiﬂoxacin is under development for ﬁrst-line therapy of
tuberculosis (TB) due to Mycobacterium tuberculosis with
the hope that it may signiﬁcantly shorten treatment duration.
Currently, it is recommended for therapy of multidrug-resistant
(MDR) TB.
Therapy for TB involves multiple drugs administered for pro-
longed periods. Standard therapy is for 6 months, while therapy
for MDR and extremely drug-resistant TB can exceed 18 months.
Multidrug TB therapy exists for two reasons. The primary reason
issuppressionofemergenceofresistance.Thesecondaryreasonis
to improve the rate and extent of M. tuberculosis cell kill, with the
goal of being able to shorten the duration of therapy.
Anexampleofresistancesuppressionwassuccessfullydemon-
stratedabout5decadesagowiththecombinationofisoniazidplus
para-aminosalicylic acid (1). An example of increasing the rate of
cellkillwasseenwiththeadditionofpyrazinamidetothestandard
TB induction regimen. Here, the rate of culture negativity signif-
icantly increased when pyrazinamide was added to the induction
regimen.
Investigators at Johns Hopkins University have indicated that
thestandardcombinationofisoniazidplusrifampin,thebasereg-
imen for susceptible M. tuberculosis, may be antagonistic with
respecttocellkill(2–4).Moxiﬂoxacin,aﬂuoroquinolone,tendsto
be able to penetrate human cells well, making it a good match for
rifampin in terms of being available both extra- and intracellu-
larly, has a reasonable rate of kill as determined in EBA studies,
and has a safety proﬁle that makes it an attractive candidate for
combination therapy with rifampin.
Itwastheintentofthissetofexperimentstoexaminerifampin
and moxiﬂoxacin alone and in combination. We examined this
combination for M. tuberculosis H37Ra in log-phase growth but
also in Wayne-Hayes level II anaerobiosis in our hollow-ﬁber in-
fection model (HFIM).
RESULTS
Organism rifampin and moxiﬂoxacin MICs and mutation fre-
quencies. The rifampin MIC (aerobic) was 0.06 mg/liter. The
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rifampin was 1.20  107. This was also determined aerobically.
Formoxiﬂoxacin,theMIC(aerobic)was0.25mg/literandthe
frequency of mutation to resistance in response to 1.5 mg/liter
could not be determined (zero colonies found on plates).
Cell kill and resistance emergence in a rifampin/moxiﬂoxa-
cin log-phase experiment. The cell kill over 28 days for all regi-
mens is shown in Fig. 1A to E. Three arms were terminated early
due to fungal contamination (rifampin at 100 mg/day [QD],
moxiﬂoxacin at 100 mg QD, and moxiﬂoxacin plus rifampin at
100 and 50 mg QD). One regimen was terminated at day 24 (ri-
fampin at 600 mg QD).
All monotherapy arms had resistance emergence during the
periodofobservation,althoughwithmoxiﬂoxacinat800mgQD,
resistance occurred only after day 21 and by day 24. With none of
thecombinationtherapyarmswasanyresistanceemergenceseen.
Monotherapy resistance emergence is displayed in Fig. 2. The
lowest-exposure combination therapy regimen is shown as a neg-
ative outcome for resistance emergence.
The nominal concentration-time proﬁles for all of the arms
were attained with acceptable accuracy and precision (all concen-
trations were achieved within approximately 10% of the nomi-
nal value). These data are available upon request.
We employed Kaplan-Meier analysis to compare single versus
combination agent therapies for time to resistance emergence, as
well as time to a 3-log kill of M. tuberculosis. The effect of combi-
nation therapy was highly signiﬁcant with regard to resistance
suppression,asshowninFig.3(P0.0006;Breslow-Gehantest).
Combinationtherapydidnotprovideatimetoa3-logcellkillthat
was signiﬁcantly different from that of monotherapy (P  0.075;
Breslow-Gehantest).Thisisconfoundedbyresistanceemergence,
whichoccurredearlyinsomemonotherapyarms;i.e.,cellkillwith
resistantsubpopulationampliﬁcationaltersthetimetoaspeciﬁed
amount of cell kill. This contrast is best pursued where there is no
resistance emergence to confound the cell kill rate outcome (see
below).
DocumentationofWayne-HayeslevelIIanaerobiosis(5)for
thenonreplicatingpersister(NRP)study.IntheHFIMstudy,O2
tensions in the liquid medium were monitored at least 5 days/
week. There were 36/53 (68%) measurements over the course of
the experiment that were 10 parts per billion (ppb) or lower. The
highest (one occasion) was 14 ppb.
FIG 1 Effects of moxiﬂoxacin alone and in combination on log-phase M. tuberculosis H37Ra. Panels: A, rifampin treatment; B, moxiﬂoxacin treatment; C,
100 mg moxiﬂoxacin in combination with three rifampin regimens; D, 200 mg moxiﬂoxacin in combination with three rifampin regimens; E, 400 mg
moxiﬂoxacin in combination with three moxiﬂoxacin regimens. Drug administrations were done once daily.
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withNilered(6)asanindicatoroftheNRPstate.Thisisshownin
Fig. 4A and B. The organisms under anaerobiosis demonstrated
clearstainingwithNilered,whereaslog-phaseorganismsdidnot.
Ithasalsobeendemonstratedpreviously(7)thatorganismsin
theNRPstateduetoWayne-HayeslevelIIanaerobiosisproducea
16-kDa protein (-crystalline protein). This is demonstrated in
Fig. 5.
GiventhedocumentationofO2tension,Nileredstaining,and
production of -crystalline protein, we conclude that the organ-
isms studied were in the NRP state due to Wayne-Hayes level II
anaerobiosis.
Cell kill and resistance emergence in a rifampin/moxiﬂoxa-
cin NRP-phase experiment. The cell kill over 17 days for all reg-
imensisshowninFig.6AtoF.Incontrasttothelog-phasegrowth
culture,thereisaconsiderablerateofcelldeathinthecontrolarm.
This is to be expected, given the stringency of the environment.
We checked the dissolved-oxygen content of the medium (see
above)andfoundthatitwasconsistentwithWayne-HayeslevelII
anaerobiosis. However, we also ascertained the ambient gas con-
tent of our system versus the headspace ambient gas in classical
Wayne-Hayes-type experiments. We were surprised to ﬁnd that
FIG 2 Emergence of resistance during drug administration. Panels: A, control; B, 300 mg rifampin QD; C, 600 mg rifampin QD; D, 200 mg moxiﬂoxacin QD;
E, 800 mg moxiﬂoxacin QD; F, 200 mg moxiﬂoxacin QD plus 100 mg rifampin QD.
FIG 3 Times to resistance emergence in M. tuberculosis H37Ra for single
versus combination chemotherapy. The difference is signiﬁcant (P  0.0006;
Breslow-Gahan test). Red is monotherapy arms. Blue is combination therapy
arms.
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this increased environmental stringency is responsible for the
deathoftheno-treatmentcontrols.Itshouldalsobenotedthatall
of the rifampin arms and two of three moxiﬂoxacin active treat-
mentarmsproducedcellkillsinexcessofthatseeninthecontrols.
There are two other important observations. The ﬁrst was that
in no instance was any resistance observed in any arm at any time
for the duration of the experiment. Given the metabolic state of
the organisms, this is not a surprise. In order for resistance to be
detected, the resistant subpopulations need to increase to a point
where the subculture volume employed has a reasonable likeli-
hood of containing at least one colony that is drug resistant. Even
if such a colony existed in our experimental setup, its inability to
grow and amplify would render the likelihood of identifying such
acolonysmall,giventhe400-lsubculturevolumerelativetothe
15 ml of the hollow-ﬁber unit. The second is that a number of the
combination chemotherapy arms did not kill faster than the con-
trol treatment. This is shown in Fig. 6C to E.
Finally, it should be noted that both isoniazid and metronida-
zole(Fig.6F)performedasexpectedundertheseconditions,with
isoniaziddemonstratingnokillinexcessoftheno-treatmentcon-
trol, while a high concentration of metronidazole (100 mg/liter)
rapidly (day 3) sterilized the unit.
FIG4 Nileredstainingoflog-phaseandNRPM.tuberculosis.(A)Organismsheldinanaerobiosisfor28daysandthoughttobeintheWayne-HayeslevelIIstate.
(Left) Organisms are visibly stained with Nile red. (Right) Organisms visualized by phase-contrast microscopy. (B) Organisms in log-phase growth. (Left) No
staining visible with Nile red. (Right) Organisms visualized by phase-contrast microscopy.
FIG 5 Presence of 16-kDa -crystalline protein, a proof of attainment of
Wayne-Hayes level II anaerobiosis.
Drusano et al.
4 mbio.asm.org July/August 2010 Volume 1 Issue 3 e00139-10Finally, the poorer performance of the combination therapy
arms caused us to formally test whether there was a signiﬁcant
difference in time to a 3-log cell kill for single versus combination
chemotherapy. In this circumstance, there was no emergence of
resistance to confound the results. The Kaplan-Meier analysis
shown in Fig. 7 demonstrated that there was a signiﬁcant differ-
ence(P0.042;Breslow-Gehantest)betweencombinationther-
apy and monotherapy, with the monotherapy groups having a
shorter time to a 3-log cell kill.
Examination of pharmacodynamic indexes for mono-
therapy versus combination therapy regimens for suppression
of ampliﬁcation of resistant subpopulations. We examined the
concentration-timeproﬁlesofthemonotherapyandcombination
therapy regimens for the log-phase organisms and used suppres-
sion of resistance as the index of success. Table 1 shows the phar-
macodynamic indexes for the monotherapy regimens that failed
and for the lowest-exposure combination therapy regimens that
suppressed less-susceptible subpopulation ampliﬁcation.
Theexposureforthe600-mgQDrifampindosefailedwiththe
observation of resistance emergence, and the free-drug area-
FIG 6 Effects of moxiﬂoxacin alone and in combination on NRP-phase (Wayne-Hayes level II anaerobiosis) M. tuberculosis H37Ra. Panels: A, rifampin
treatment;B,moxiﬂoxacintreatment;C,100mgmoxiﬂoxacinincombinationwiththreerifampinregimens;D,200mgmoxiﬂoxacinincombinationwiththree
rifampin regimens; E, 400 mg moxiﬂoxacin in combination with three moxiﬂoxacin regimens; F, effect of continuous infusion of isoniazid and continuous
infusion of metronidazole. Drug administrations were done once daily.
FIG 7 Times to achievement of a 3-log kill of M. tuberculosis H37Ra cells in
the NRP phase for single versus combination chemotherapy. The difference is
signiﬁcant(P0.042;Breslow-Gahantest).Redismonotherapyarms.Blueis
combination therapy arms.
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cin 800-mg-equivalent exposure given daily, failure due to resis-
tance was late but occurred at a free-drug AUC/MIC ratio of
177.2.
In contrast, the combination regimen of 100 mg rifampin plus
100 mg moxiﬂoxacin suppressed the ampliﬁcation of less-
susceptiblepopulationsuntiltheendoftheexperiment.Thefree-
drug AUC/MIC ratio for rifampin in this combination was 24.2,
and for moxiﬂoxacin it was 21.5. The combination regimen re-
duced the drug exposure required for resistance suppression by
circa 7-fold for rifampin and by circa 8-fold for moxiﬂoxacin.
DISCUSSION
Moxiﬂoxacin is the newest agent being extensively evaluated for
ﬁrst-line status for TB therapy. Rifampin is the backbone of cur-
rentTBtherapy,whenthepathogenissusceptibletoit.Anumber
ofinvestigatorshaveindicatedthatisoniazidisactuallyantagonis-
tic when part of the standard four-drug therapy in mouse experi-
ments (2–4). Consequently, we decided to examine the combina-
tion of moxiﬂoxacin plus rifampin.
OneoftheuniqueaspectsoftherapyforTBisthatitishypoth-
esized that there are multiple physiological states of the pathogen
thathaveanimpactontheabilitytokilltargetorganismsandalso
mayhaveanimpactonthedurationoftherapynecessarytoattain
atrueclinicalcure(8).Oneofthesephysiologicalstatesisthought
toresultinasubpopulationbeingintheNRPstate(5,9).Produc-
tion of Wayne-Hayes level II anaerobiosis has been used as a tool
for studying M. tuberculosis in this state. We decided to examine
the combination of moxiﬂoxacin plus rifampin against M. tuber-
culosis in log-phase growth but also in the NRP state.
The interaction of antimicrobial agents is often thought of as
beingsynergistic,additive,orantagonistic(10).Whileitisauseful
frame of reference, it is critical to recognize that this is an incom-
plete way to think of drug-drug interaction for effect. It is impor-
tant to state what the endpoint is that is being evaluated. Gener-
ally,theinteractionisevaluatedasafunctionofcellkill.However,
this is not the only endpoint that is clinically important. The abil-
ity of agents in combination to suppress the ampliﬁcation of re-
sistantsubpopulationsisarguablyasimportantasormoreimpor-
tant than the ability to kill organisms at an optimal rate. Our
laboratoryhasrecentlydemonstratedthattheseendpointsmaybe
dichotomous, as we examined meropenem plus tobramycin
against Pseudomonas aeruginosa (11). In this evaluation, we
looked at both of these endpoints.
Whenthemoxiﬂoxacin-rifampininteractionwasexaminedin
log-phase growth organisms, the outcome was quite clear (Fig. 1
and 2). Monotherapy with either moxiﬂoxacin or rifampin dem-
onstrated a good organism kill in the ﬁrst 1 to 2 weeks of the
experiment. After this point, clear regrowth was seen. Examina-
tionofgrowthondrug-containingplatesdemonstratedthatinall
ofthemonotherapyarmstherewasemergenceofresistanceinthe
ﬁrst week to 10 days. The single exception was high-dose moxi-
ﬂoxacin at 800 mg QD, where resistance emergence was not seen
until day 24 of the experiment.
Combination chemotherapy outcomes were very clear. In no
instance was any resistance emergence observed for the full dura-
tion of the experiment. In order to test for differences between
monotherapy and combination agent therapy, we employed
Kaplan-Meierproductlimitestimation.Forcellkill,weemployed
the time needed to achieve a 3-log decline in colony counts from
the baseline. For resistance emergence, we looked at the time to
the ﬁrst observation of resistant colonies on drug-containing
plates exceeding the baseline number. No signiﬁcant difference
was seen between monotherapy and combination therapy groups
inthetimeneededtoachievea3-logdeclineintotalcolonycounts
(P  0.075), but a highly signiﬁcant difference was seen for the
time to identiﬁcation of resistant colonies (Fig. 3; P  0.0006).
The main effect identiﬁable for combination therapy with log-
phaseorganismsissuppressionofresistance.Giventheconfound-
ing between resistance emergence and the rate of decline of the
total population burden, it was not clear whether there was truly
no difference in the rate of kill. For this evaluation, we chose to
examinethesecondexperimentwithorganismsintheNRPphase.
One of the ﬁndings in this population is that there was no
resistance emergence seen in any regimen evaluation at any time.
Thisisnotsurprisingforanumberofreasons.First,thenumberof
baseline organisms in the NRP state was relatively low (as is
thoughttobethecaseclinically).Second,thestringentconditions
caused cell death over time in the no-treatment control. There-
fore, the number of organisms in which resistance can emerge
goesdownwithtime.Third,themetabolicstateofNRPorganisms
is such that there is no growth, and hence, organisms best able to
withstand drug pressure cannot amplify because no growth is oc-
curring. Also, little in the way of protein synthesis occurs (12), so
that mechanisms such as efﬂux pump induction and expression
cannot provide protection.
However,thelackofresistancemeansthatthispopulationcan
be used to examine for the effect of combination therapy on the
rate of cell kill without confounding. Examining Fig. 6 and 7
shows that there was a signiﬁcant difference between mono-
therapyandcombinationagenttherapywithrespecttothetimeit
took to achieve a 3-log kill of the total bacterial burden from the
baseline. In this instance, however, the monotherapy arms
achieved this reduction in the bacterial burden signiﬁcantly more
rapidlythanthecombinationtherapyregimensdid.Thisindicates
that the combination of moxiﬂoxacin plus rifampin is somewhat
antagonistic with respect to cell kill but is synergistic with respect
to suppression of emergence of resistance (seen in the log-phase
organism experiment). It should also be noted that rifampin out-
performed moxiﬂoxacin in the NRP experiment, indicating that
this is still the standard for NRP-phase organisms but that moxi-
ﬂoxacin is a welcome addition.
We looked at the ability to suppress less-susceptible subpopu-
lationsfromamplifyingquantitativelybycalculatingthefree-drug
AUC/MICratiosofbothmoxiﬂoxacinandrifampinforthelargest
monotherapy failure exposures (rifampin at 600 mg QD and
moxiﬂoxacin at 800 mg QD) and the lowest combination therapy
regimensuccessfulatsuppressingresistanceemergence(rifampin
at 100 mg QD plus moxiﬂoxacin at 100 mg QD). The exposures
TABLE 1 Pharmacodynamic parameter values of failing and
succeeding single and combination therapy regimens for resistance
suppression
Regimen
AUC/MIC ratio of free: Resistance
suppression Rifampin Moxiﬂoxacin
600 mg rifampin QD 168.2 Failure
800 mg moxiﬂoxacin QD 177.2 Failure
100 mg rifampin QD  100
mg moxiﬂoxacin QD
24.2 21.5 Success
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7-fold (rifampin) and 8-fold (moxiﬂoxacin) lower than those of
monotherapyregimensthatfailed.Clearly,therewasasynergistic
interaction between these agents with respect to resistance emer-
gence.
The conclusion that one can draw is that it is likely that the
moxiﬂoxacin-rifampin combination is somewhat analogous to
the isoniazid-rifampin combinations in that there may be some
antagonism with respect to rates of overall reduction of the bac-
terial burden but that there is clearly protection with regard to
resistance emergence. The implication is that this combination is
welcome as another excellent choice to add to the clinician’s ar-
mamentarium but it may not mediate a major reduction in the
durationoftherapyforwild-typeM.tuberculosisinfections(butis
hugelyimportantforMDRTBtherapy).Indeed,onelargeclinical
trial in which moxiﬂoxacin was substituted for isoniazid (13) has
demonstratedthispointrecently.However,another,wheremoxi-
ﬂoxacin was substituted for ethambutol (14), demonstrated a
beneﬁt with respect to the time to culture negativity. It would be
importanttointerpretthisdifferencewithrespecttothedegreeof
cell kill antagonism for the rifampin-isoniazid combination ver-
sus the rifampin-moxiﬂoxacin combination and to evaluate
rifampin-isoniazid and moxiﬂoxacin in combination in this in
vitro system.
MATERIALS AND METHODS
Bacterial isolate. M. tuberculosis H37Ra (ATCC 25177; American Type
Culture Collection) was used in our studies (it should be noted that this
isolate is not the same as H37Rv with respect to MIC values and other
characteristics and that neither may reﬂect those of wild-type isolates).
Bacterial cultures were stored at 80°C in Middlebrook 7H9 broth with
10% oleic acid-albumin-dextrose-catalase (OADC) and 0.025% Tween
80 (Becton Dickinson), here called “medium,” and aliquots were thawed
foreachstudy.Thecultureswereincubatedin5%CO2at37°Cinmedium
for 4 days to achieve exponential-phase growth. NRP M. tuberculosis
H37Ra was generated using the Wayne-Hayes model (5). Brieﬂy, M. tu-
berculosis H37Ra was grown in Dubos Tween albumin broth. The culture
was slowly stirred in a sealed glass bottle with a 1:1 headspace-to-volume
ratio for 28 days at 37°C.
Antimicrobial agents. Rifampin was obtained from the pharmacy at
Albany Medical College (Albany, NY). Stock solutions of this antibiotic
werepreparedinsterilewater,andaliquotswerestoredat–80°C.Foreach
study,asampleofthedrugwasthawedanddilutedtothedesiredconcen-
tration in sterile water or Middlebrook 7H9 broth and used immediately.
Moxiﬂoxacin was the kind gift of Bayer Pharmaceuticals. Stock solu-
tions of this antibiotic were prepared in sterile water, and aliquots were
stored at –80°C. For each study, a sample of the drug was thawed and
diluted to the desired concentration in sterile water or Middlebrook 7H9
broth and used immediately.
MIC determination. H37Ra MIC values were determined by plating
10 lo fa1 106-CFU/ml concentration of culture onto Middlebrook
7H10 agar plus OADC containing geometric 2-fold dilutions of rifampin
ormoxiﬂoxacin.Plateswereincubatedat37°C,andresultswerereadafter
21 days of incubation. The MIC was deﬁned as the lowest concentration
that allowed growth of M. tuberculosis that was 1% of that of untreated
controls. MIC testing was performed as described by CLSI (17). This
determination was conducted aerobically.
Mutation frequency determinations. M. tuberculosis H37Ra was
grown to exponential phase in 7H9 broth as described above. On the 4th
day, the mutation frequency in the cultures was determined by plating
5 ml of a log-phase culture of M. tuberculosis onto Middlebrook 7H10-
OADC plates containing either 32 the MIC of rifampin or 6 the MIC
ofmoxiﬂoxacin.Themutationfrequencywasdeterminedafter21daysof
incubation at 37°C. This determination was performed aerobically.
Measurement of dissolved O2. Dissolved-O2 measurements were
taken with a Mettler, Toledo InPro6900 sensor and an O2 4,100-ppb
transmitter (Mettler, Toledo, Bedford, MA).
Nileredassay.Nilered(Sigma-Aldrich,St.Louis,MO)wasdissolved
inethanolat0.5mg/mlandstoredat20°C.Forstaining,1lofNilered
solution was added to 50 l of bacterial solution and the mixture was
incubated at 37°C for 10 min. Samples were washed three times with
phosphate-bufferedsaline(PBS)andthenmountedinglycerolonmicro-
scopeslides.CellswereviewedusingaCarlZeiss510METAlaserscanning
microscope at a wavelength of 514 nm.
Detectionof-crystallineprotein.TheNRPcultureswereharvested
onday28ofNRPgeneration,centrifugedat3,000gfor20min,washed
three times with PBS containing protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO) and Tween 80 (PBSIT), and resuspended to 1 ml
in PBSIT. Samples were frozen and thawed 10 times using a dry ice bath
anda37°Cwaterbath.TotalcellularproteinswereextractedwithaMini-
BeadBeater (Biospec, Bartlesville, OK) using an equal volume of 0.1-mm
glass beads (Sigma-Aldrich, St. Louis, MO). Cell debris and beads were
centrifuged at 16,000  g, and the supernatant was collected. Cellular
proteins were prepared with 2 sodium dodecyl sulfate (SDS) sample
buffer (125 mM Tris-HCl [pH 6.8], 4% SDS, 20% glycerol, 0.005% bro-
mophenol blue) and heated at 95°C for 5 min. Cellular proteins were
stainedwithCoomassieblueandseparatedbySDS-PAGEwithaconstant
100 V on 12% acrylamide gels (15).
HFIM.TheHFIMpermitsustosimulatetheconcentration-timepro-
ﬁle of any dose of antibiotic. A computer-controlled syringe pump deliv-
ers the antibiotic into a central reservoir in the required amount at the
desired schedule of administration. Fresh medium is pumped into the
systemwhiledrug-containingmediumisisovolumetricallyremovedfrom
thesystematratesprogrammedbytheinvestigatortosimulatethedesired
drug half-life (t1/2).
In these experiments, 15 ml of M. tuberculosis H37Ra was inoculated
into the peripheral compartments of hollow-ﬁber cartridges at a concen-
tration of 1  106 to 5  106 CFU/ml.
Using human pharmacokinetic parameters (t1/2 of 12 h and 50% pro-
tein binding for moxiﬂoxacin, t1/2 of 3.5 h and 84% protein binding for
rifampin),thefree-drugserumconcentration-timeproﬁlesofmoxiﬂoxa-
cinandrifampinweresimulated.Theregimenswerethesameforboththe
28-daylog-phasegrowthstudyandthe17-dayNRPWayne-HayeslevelII
anaerobiosis study. The rifampin-only regimens were 100, 200, and
600mgQD.Formoxiﬂoxacin,theywere100,200,and800mgQD.These
regimens were chosen to be at or below the currently recommended and
licensed drug doses. The exception is the 800-mg moxiﬂoxacin dose,
which was chosen to determine if it is better for NRP therapy. For com-
bination regimens, all possible combinations (n  9) of 100, 200, and
600mgofrifampinweremadewith100,200,and400mgofmoxiﬂoxacin.
For the arms where combination therapy was employed, the correct
and quite different t1/2s of rifampin and moxiﬂoxacin were developed by
using the approach of Blaser (16). For the 28-day log-phase study, bacte-
rialsamples(400l)weretakenfromeachhollow-ﬁbercartridge,washed
(samples are taken from each hollow-ﬁber system and washed twice with
sterilesalinebycentrifugationat1,500g;thesamplesarethensonicated
andvortexedtobreakupanyclumpsandplatedon7H10-OADCagarfor
quantitative culture) to prevent drug carryover, and then quantitatively
cultured on drug-free agar and agar supplemented with 32 the MIC of
rifampin or 6 the MIC of moxiﬂoxacin to determine the effect of each
treatment regimen on the total and rifampin- or moxiﬂoxacin-resistant
populations, respectively. After 21 days of incubation, the colonies were
counted. The 17-day NRP study was performed identically.
The pharmacokinetic proﬁles simulated for rifampin and moxiﬂoxa-
cin were conﬁrmed by liquid chromatography-tandem mass spectrome-
try.Thecentralreservoirwassampledon15occasionsover48h.Thedata
were modeled and considered acceptable if clearance and volume esti-
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conducted on two separate occasions.
Pharmacokinetic methods. Concentration-time proﬁles were ana-
lyzed employing the ADAPT II package of programs of D. Z. D’Argenio
and A. Schumitzky, Biomedical Simulations Resource, University of
Southern California (identiﬁcation module: maximum-likelihood esti-
mation). As computer-controlled infusion pumps drove the proﬁle, a
one-compartment open model with zero-order input and ﬁrst-order
elimination was employed.
Statistical analysis. We examined the time to resistance emergence
andthetimetosterilityusingaKaplan-Meierestimator.Theanalysiswas
performed using SYSTAT for Windows v11. A P value of 0.05 was con-
sidered signiﬁcant.
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